Factors associated with disease-specific survival of patients with non-small cell lung cancer

Abstract

Objective:Lung cancer is a global public health problem and is associated with high mortality. Lung cancer could be largely avoided by reducing the prevalence of smoking. The objective of this study was to analyze the effects of social, behavioral, and clinical factors on the survival time of patients with non-small cell lung cancer treated at Cancer Hospital I of the José Alencar Gomes da Silva National Cancer Institute, located in the city of Rio de Janeiro, Brazil, between 2000 and 2003. Methods:This was a retrospective hospital cohort study involving 1,194 patients. The 60-month disease-specific survival probabilities were calculated with the Kaplan-Meier method for three stage groups. The importance of the studied factors was assessed with a hierarchical theoretical model after adjustment by Cox multiple regression. Results:The estimated 60-month specific-disease lethality rate was 86.0%. The 60-month disease-specific survival probability ranged from 25.0% (stages I/II) to 2.5% (stage IV). The performance status, the intention to treat, and the initial treatment modality were the major prognostic factors identified in the study population. Conclusions:In this cohort of patients, the disease-specific survival probabilities were extremely low. We identified no factors that could be modified after the diagnosis in order to improve survival. Primary prevention, such as reducing the prevalence of smoking, is still the best method to reduce the number of people who will suffer the consequences of lung cancer.

FOXP3 facilitates the invasion and metastasis of non‑small cell lung cancer cells through regulating VEGF, EMT and the Notch1/Hes1 pathway

“…Every year, 1.8 million people are diagnosed with lung cancer and 1.6 million people die of the disease (3). Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and accounts for ~85% of all cases (4). Despite advances and improvements in surgical treatment for early-stage NSCLC, recurrence and metastasis are still the main factors affecting prognosis (5).…”

Epigallocatechin‐3‐gallate inhibited cancer stem cell–like properties by targeting hsa‐mir‐485‐5p/RXRα in lung cancer

“…Lung cancer is well known as a leading cause of cancer‐related death worldwide, with a high mortality rate . Approximately 85% of patients with cancer are diagnosed with non–small‐cell lung cancer (NSCLC), one of the most predominant pathological types of lung cancers . Although considerable progress has been made in the treatment of NSCLC, the 5‐year overall survival rate of patients with NSCLC still remains poor, mainly due to the lack of early diagnosis and effective treatments.…”

MicroRNA-373 Inhibits Cell Proliferation and Invasion via Targeting BRF2 in Human Non-small Cell Lung Cancer A549 Cell Line

“…Lung cancer is the most common solid tumor, and it is well-known as a leading cause of cancer-related death worldwide due to its high mortality rate [ 1 , 2 ]. Approximately 85% of cancer patients have non-small cell lung cancer (NSCLC), one of the most predominant pathological types of lung cancers, and the incidence rates increases year after year [ 3 ]. The 5-year overall survival (OS) rate of NSCLC patients remains very poor mainly owing to its late diagnosis and the paucity of effective treatments [ 1 ].…”